蒲地蓝联合利巴韦林对小儿手足口病的临床价值

The clinical value of pudilan combined with ribavirin to treat pediatric hand foot and mouth disease

目的评估蒲地蓝联合利巴韦林治疗小儿手足口病的临床价值。方法选取小儿手足口病80例,随机分为试验组和对照组,各40例,一般资料无明显差异,试验组:使用蒲地蓝0.4～0.8 ml/(kg·d)+利巴韦林10～15 mg/(kg.d),分三次口服,以连续服用5 d为1疗程;对照组:只使用利巴韦林10～15 mg/(kg·d),分三次口服,以连续服用5 d为1疗程。观察1疗程后的治疗效果。结果试验组的手足口部皮疹持续时间均比对照组少,且退热时间比对照组快,因而住院时间比对照组少,其差异军有统计学意义。试验组的有效率为95.0%;而对照组的有效率为77.5%。对照组的治愈率明显低于试验组,且差异有统计学意义(χ2=5.1646,P<0.05)。结论联合使用蒲地蓝和利巴韦林,较单用利巴韦林的有效率高,能加速皮疹消退和退热时间,是一种值得借鉴的治疗方案。

Objective To assess the clinical value of pudilan combined with ribavirin to treat pediatric hand foot and mouth disease. Methods Selected 80 cases of pediatric hand foot and mouth disease and randomly divided into experimental group and matched group. The general date of two groups had no significant difference. Experimental group： pudilan 0.4 -0. 8 mL/（ kg . d） ＋ ribavirin 10 - 15 mg/（ kg . d） , in three oral, and 5 days as a course of treatment. Matched group： only ribavirin 10 - 15 mg/（kg . d） , in three oral, and 5 days as a course of treatment. Results The duration of in hand foot and mouth of experimental group was less than matched group, and so as the duration of fever. So the hospital stays of experimental group was less than matched group. The effective rate of experimental group was 95.0% , while the matched group was only 77. 5%. Obviously the experimental group had the better than the matched group and the difference was statistically sig- nificant （ = 5.1646, P 〈 0. 05 ）. Conclusion Pudilan combined with ribavirin to treat pediatric hand foot and mouth disease had better effect than only ribavirin. This can shorten the duration of fever and rash, and worthes to draw lessons from.